ViroPharma's FDA challenge dismissed by federal court

ViroPharma lost a U.S. court bid to delay generic competition for its key product, Vancocin. The company had challenged FDA's choice to allow generics makers to launch their versions of the infection fighter, without first conducting human trials. Report